State

;

Letter to the DC Council supporting the PrEP DC Amendment Act (B26-0159)

Feb 20, 2026 | ,

We, the undersigned HIV service providers, advocates, and public health organizations in the District of Columbia, write in strong support of the PrEP DC Amendment Act (B26-0159) and urge the Council to pass the bill without change on its final reading. Requiring coverage of all PrEP drugs is essential to increasing uptake, supporting adherence, and reducing new HIV cases in the District. Allowing individuals and their providers to choose the PrEP option that works best for them reflects current best practices in HIV prevention and is consistent with current federal protections.

read more

Comments to Colorado Dept of Health Care Policy & Financing supporting the prohibition of prior authorization for HIV treatment and prevention in Medicaid

Feb 6, 2026 | ,

We urge Colorado to maintain the prohibition of prior authorization for HIV treatment and prevention in Medicaid. Timely access to guideline-recommended HIV treatment and prevention is critical for both individual and public health. These policies align with rapid scientific advancement. Reinstating prior authorization would disproportionately harm the most vulnerable. 

read more

Letter to Missouri House Health Committee supporting HB1941 to ban copay accumulators

Feb 3, 2026 | ,

We strongly support House Bill 1941 which ensures that health insurers accept and count payments made on behalf of patients toward their deductibles and out-of-pocket maximums. Copay accumulators are harmful policies increasingly implemented by insurers, employers, and pharmacy benefit managers (PBMs). Under these policies, copay assistance provided by drug manufacturers does not count toward patients’ cost-sharing obligations, such as deductibles and out-of-pocket maximums. While patients can initially use the assistance to afford their medications, they often face unexpected and substantial costs later in the year when the assistance runs out, leaving them unable to pay for their prescriptions.

read more

Comments on Oregon PDAB draft 2026 drug review preliminary list

Jan 16, 2026 | ,

Affordability reviews of HIV medications are unlikely to fully capture the complexity and interdependence of safety net programs, which not only ensure affordability for patients but also sustain the broader HIV care infrastructure. While we recognize the Board’s current position to not seek upper payment limit authority, reviewing medications like Biktarvy, Descovy, and Emtricitabine-Tenofovir based on list price alone (despite their actual affordability for the vast majority of patients) could have significant unintended consequences. Such reviews risk creating systemic uncertainty for manufacturers, healthcare providers, and safety net programs that rely heavily on drug rebates to fund essential wraparound services. Ultimately, this instability could undermine the delicate balance required for continued investment in the transformative advancements our community relies on, including longer-acting treatments, preventive therapies, vaccines, and the pursuit of an eventual cure.

read more

Pin It on Pinterest